Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle – a focus on benefits and risks

References

• Eichler HG, Pignatti F, Flamion B, et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov. 2008;7(10):818–826.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med. 2008;5(3):e67.
   PubMed Web of Science ®Google Scholar
• Duijnhoven RG, Straus SM, Raine JM, et al. Number of patients studied prior to approval of new medicines: a database analysis. PLoS Med. 2013;10(3):e1001407.
   PubMed Web of Science ®Google Scholar
• Langedijk J, Whitehead CJ, Slijkerman DS, et al. Extensions of indication throughout the drug product lifecycle: a quantitative analysis. Drug Discov Today. 2016;21(2):348–355.
   PubMed Web of Science ®Google Scholar
• Liu F, Jagannatha A, Yu H. Towards drug safety surveillance and pharmacovigilance: current progress in detecting medication and adverse drug events from electronic health records. Drug Saf. 2019;42(1):95–97.
   PubMed Web of Science ®Google Scholar
• Santoro A, Genov G, Spooner A, et al. Promoting and protecting public health: how the european union pharmacovigilance system works. Drug Saf. 2017;40(10):855–869.
   PubMed Web of Science ®Google Scholar
• Moseley J, Vamvakas S, Berntgen M, et al. Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines. Br J Clin Pharmacol. 2020;86(6):1034–1051. .
   PubMed Web of Science ®Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). M4E(R2) guideline: the common technical document – efficacy. 2016.
   Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). E2C(R2) Guideline: periodic Benefit-Risk Report (PBRER). 2012.
   Google Scholar
• Califf RM. Benefit-Risk assessments at the us food and drug administration: finding the balance. JAMA. 2017;317(7):693–694.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Day 180 joint response assessment report - Overview template rev. July.18. 2018.
   Google Scholar
• Arlett P, Portier G, De Lisa R, et al. Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance risk assessment committee. Nat Rev Drug Discov. 2014;13(5):395–397. .
   PubMed Web of Science ®Google Scholar
• Potts J, Genov G, Segec A, et al. Improving the safety of medicines in the european union: from signals to action. Clin Pharmacol Ther. 2020;107(3):521–529.
   PubMed Web of Science ®Google Scholar
• Bouvy JC, Huinink L, De Bruin ML. Benefit-risk reassessment of medicines: a retrospective analysis of all safety-related referral procedures in Europe during 2001-2012. Pharmacoepidemiol Drug Saf. 2016;25(9):1004–1014.
   PubMed Web of Science ®Google Scholar
• Brown JP, Wing K, Evans SJ, et al. Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013-2017. BMJ Open. 2019;9(10):e028133.
   PubMed Web of Science ®Google Scholar
• Farcas A, Balcescu T, Anghel L, et al. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012. Expert Opin Drug Saf. 2020;19(6):755–762.
   PubMed Web of Science ®Google Scholar
• Sekine S, Pinnow EE, Wu E, et al. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions. Clin Pharmacol Ther. 2016;100(1):102–108.
   PubMed Web of Science ®Google Scholar
• Ishiguro C, Misu T, Iwasa E, et al. Analysis of safety-related regulatory actions by Japan’s pharmaceutical regulatory agency. Pharmacoepidemiol Drug Saf. 2017;26(11):1314–1320.
   PubMed Web of Science ®Google Scholar
• Mostaghim SR, Gagne JJ, Kesselheim AS. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study. BMJ. 2017;358:j3837.
   PubMedGoogle Scholar
• Insani WN, Pacurariu AC, Mantel-Teeuwisse AK, et al. Characteristics of drugs safety signals that predict safety related product information update. Pharmacoepidemiol Drug Saf. 2018;27(7):789–796.
   PubMed Web of Science ®Google Scholar
• Shepshelovich D, Tibau A, Goldvaser H, et al. Postmarketing modifications of drug labels for cancer drugs approved by the US food and drug administration between 2006 and 2016 with and without supporting randomized controlled trials. J Clin Oncol. 2018;36(18):1798–1804.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Murakami M, Masuyama K, et al. The association between concerns toward adverse reactions during pre-approval drug reviews and the post-approval addition of clinically significant adverse reactions to package inserts: a retrospective analysis of pre-approval drug review reports and safety updates. Pharmacoepidemiol Drug Saf. 2018;27(11):1265–1276.
   PubMed Web of Science ®Google Scholar
• Shepshelovich D, Tibau A, Goldvaser H, et al. Postmarketing Safety-Related modifications of drugs approved by the US Food and Drug Administration between 1999 and 2014 without randomized controlled trials. Mayo Clin Proc. 2019;94(1):74–83.
   PubMed Web of Science ®Google Scholar
• Fujikawa M, Ono S. Analysis of Safety-Related regulatory actions for new drugs in Japan by nature of identified risks. Pharmaceut Med. 2017;31(5):317–327.
   PubMed Web of Science ®Google Scholar
• Nakayama H, Matsumaru N, Tsukamoto K. Safety-Related regulatory actions and risk factors for anticancer drugs in Japan. Pharmaceut Med. 2019;33(1):45–52.
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14(1):10.
   PubMed Web of Science ®Google Scholar
• Saluja S, Woolhandler S, Himmelstein DU, et al. Unsafe drugs were prescribed more than one hundred million times in the United States before being recalled. Int J Health Serv. 2016;46(3):523–530.
   PubMed Web of Science ®Google Scholar
• Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open. 2018;8(1):e019759.
   PubMed Web of Science ®Google Scholar
• Craveiro NS, Lopes BS, Tomas L, et al. Drug withdrawal due to safety: a review of the data supporting withdrawal decision. Curr Drug Saf. 2020;15(1):4–12.
   PubMed Web of Science ®Google Scholar
• Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R. FDA safety actions for antidiabetic drugs marketed in the US, 1980-2015. Int J Risk Saf Med. 2016;28(4):197–211.
   PubMed Web of Science ®Google Scholar
• Zeitoun JD, Lefevre JH, Downing NS, et al. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study. Pharmacoepidemiol Drug Saf. 2016;25(6):687–694.
   PubMed Web of Science ®Google Scholar
• Downing NS, Shah ND, Aminawung JA, et al. Postmarket safety events among novel therapeutics approved by the us food and drug administration between 2001 and 2010. JAMA. 2017;317(18):1854–1863. .
   PubMed Web of Science ®Google Scholar
• Schick A, Miller KL, Lanthier M, et al. Evaluation of Pre-marketing factors to predict post-marketing boxed warnings and safety withdrawals. Drug Saf. 2017;40(6):497–503.
   PubMed Web of Science ®Google Scholar
• Ikeda J, Kaneko M, Narukawa M. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: a cohort study focused on first-in-class drugs. Pharmacoepidemiol Drug Saf. 2018;27(12):1393–1401.
   PubMed Web of Science ®Google Scholar
• Pacurariu AC, Hoeve CE, Arlett P, et al. Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues? Pharmacoepidemiol Drug Saf. 2018;27(2):168–173. .
   PubMed Web of Science ®Google Scholar
• Pinnow E, Amr S, Bentzen SM, et al. Postmarket safety outcomes for New Molecular Entity (NME) drugs approved by the food and drug administration between 2002 and 2014. Clin Pharmacol Ther. 2018;104(2):390–400. .
   PubMed Web of Science ®Google Scholar
• Bulatao I, Pinnow E, Day B, et al., Postmarketing Safety-Related regulatory actions for new therapeutic biologics approved in the United States 2002–2014: similarities and differences with new molecular entities. Clin Pharmacol Ther. 108(6): 1243–1253. 2020. .
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Tibau A, Raanani P, et al. Safety-Related postmarketing modifications of drugs for hematological malignancies. Acta Haematol. 2020;143(1):73–77.
   PubMed Web of Science ®Google Scholar
• Ikeda J, Kaneko M, Narukawa M. Post-marketing safety-related regulatory actions on first-in-class drugs: a double-cohort study. J Clin Pharm Ther. 2020;45(3):496–502.
   PubMed Web of Science ®Google Scholar
• Kim J, Nair A, Keegan P, et al. Evaluation of serious postmarket safety signals within 2 years of FDA approval for new cancer drugs. Oncologist. 2020;25(4):348–354. .
   PubMed Web of Science ®Google Scholar
• Ehmann F, Papaluca M, Di Giuseppe F, et al. Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union. Expert Opin Pharmacother. 2015;16(6):903–911.
   PubMed Web of Science ®Google Scholar
• Minnema LA, Giezen TJ, Gardarsdottir H, et al. Post-marketing dosing changes in the label of biologicals. Br J Clin Pharmacol. 2019;85(4):715–721.
   PubMed Web of Science ®Google Scholar
• Ebbers HC, Mantel-Teeuwisse AK, Moors EHM, et al. A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals. Drug Saf. 2012;35(5):417–427.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Arzerra – withdrawal of the marketing authorisation in the European Union (EMA/149805/2019). 28 February 2019.
   Google Scholar
• European Medicines Agency. Kesimpta: pending EC decision. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/kesimpta. Accessed 19 March 2021.
   Google Scholar
• Adlan AM, Lip GY. Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation. Drug Saf. 2013;36(2):93–110.
   PubMed Web of Science ®Google Scholar
• European Commission. Commission Implementing Regulation (EU) No 520/2012 of 19 June 2012 on the performance of pharmacovigilance activities provided for in Regulation (EC) No 726/2004 of the European Parliament and of the Council and Directive 2001/83/EC of the European Parliament and of the Council. Off J Eur Union. 2012;L 159/5–25.
   Google Scholar
• European Medicines Agency. CHMP Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 (EMA/CHMP/509951/2006, Rev. 1). 25 February 2016.
   Google Scholar
• European Medicines Agency. CHMP Guideline on procedures for the granting of a marketing authorisation under exceptional circumstances, pursuant to article 14 (8) of Regulation No 726/2004 (EMEA/357981/2005). 15 December 2005.
   Google Scholar
• European Medicines Agency. PDCO/CAT/CMDh/PRAC/CHMP Scientific guidance on post-authorisation efficacy studies (EMA/PDCO/CAT/CMDh/PRAC/CHMP/261500/2015). 12 October 2016.
   Google Scholar
• European Commission. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Off J Eur Communities. 2001;L 311/67–128.
   Google Scholar
• European Medicines Agency, Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1) (EMA/816292/2011 Rev 1). 9 December 2013.
   Google Scholar
• European Medicines Agency. List of medicines under additional monitoring. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring. Accessed 19 March 2021.
   Google Scholar
• European Medicines Agency. Screening for adverse reactions in EudraVigilance (EMA/849944/2016). 19 December 2016.
   Google Scholar